Media reports in China have revealed that the Center for Drug Evaluation of China’s National Medical Products Administration has accepted Sinopharm’s application for approval of two Covid-19 vaccines.
According to the Global Times newspaper, the authorization will take effect on January 1. It explained that the authorization was given to the Chinese company with which Morocco has signed a contract to obtain large quantities of doses of one of the vaccines developed, the BBIBP-CorV vaccine.
Health Minister Khalid Ait Taleb said Thursday that Morocco has purchased 65 million doses of the Chinese Sinopharm vaccine and the British AstraZeneca.
Health officials in the Kingdom have not revealed the launch date of the vaccination campaign. However, they said that preparations are in very advanced stages.
The Department of Medicines and Pharmacy has received the clinical trial documents for the vaccine developed by the Chinese laboratories Sinopharm, and is in the process of registering the vaccine subject to this extensive research, and thus the authorization to market it.
The authorization to market the vaccine in Morocco is like a birth certificate in the drug market, which is extracted after the technical and chemical tests to which the vaccine will be subjected in the national drug control laboratories.
In order to obtain the authorization, the vaccine would have to meet delicate standards such as quality, safety, and efficacy in relation to its side effects, to determine the conditions of its use.